Olsart® 10 Tablet: Each film coated tablet contains Olmesartan medoxomil BP 10 mg.
Olsart® 20 Tablet: Each film coated tablet contains Olmesartan medoxomil BP 20 mg.
Olsart® 40 Tablet: Each film coated tablet contains Olmesartan medoxomil BP 40 mg.
Olmesartan medoxomil (Olsart®) is an angiotensin II receptor antagonist. It is a prodrug which is converted to olmesartan during absorption from the gastrointestinal tract.
Mode of action:
Olmesartan blocks the binding of Angiotensin-II with AT₁ receptor of vascular smooth muscle which results vasodilation, less Na⁺ & H₂O retention and ultimately controls blood pressure.
Pharmacokinetics:
After oral administration Olmesartan medoxomil is rapidly absorbed and converted to olmesartan. Peak plasma concentrations of olmesartan occurred within 1-3 hours after administration. The elimination half-life is 10-15 hours. Approximately 40% of olmesartan was excreted by the kidneys, the remainder being excreted in faeces.
It is indicated for the treatment of hypertension.
For the treatment of hypertension initially 10 mg once daily; if necessary increased to 20 mg once daily; maximum 40 mg daily.
Patients with Renal & Hepatic impairment: Maximum 20 mg daily.
Chance of drug-drug interaction is very low because Olmesartan medoxomil is not metabolized by Cytochrome P450 enzyme.
USFDA Pregnancy category C. The safety of Olmesartan medoxomil during pregnancy & lactation has not been established.
Precautions should be taken for patients with severe congestive heart failure and renal artery stenosis. If diarrhea or vomiting occurs then precautions should be taken for the next use of Olmesartan medoxomil.
Keep out of reach of children. Store in a dry place, below 25°C temperature and protected from light.